Searcharxiv⌕ Search

arXiv subjects

Yuan Li Shen

Publications and source records attributed to Yuan Li Shen.

2 recordsLinked to original sources

Implementing the principal stratum strategy for intercurrent events with survival outcomes: a tutorial

The International Council for Harmonization (ICH) E9 (R1) addendum provides the estimand framework to formulate treatment effects in a clinical trial. One of the attributes of an estimand the framework describes is intercurrent events. Among the five strategies to intercurrent events the guidance lists, the principal stratum strategy is the most conceptually and technically challenging because it defines treatment effects on unobserved strata. Its application to survival outcomes is particularly inaccessible to practitioners. This tutorial reviews the methodology and implementation of the estimand framework with the principal stratum strategy to address intercurrent events with survival outcomes. We illustrate using a clinical trial in oncology and focus on a simple case with binary treatment and a single binary intercurrent event of discontinuation of the assigned treatment. We define the causal effects and review two main methods for estimating the effects: the mixture model method and the weighting method. For each method, we elaborate the associated assumptions, models, sensitivity analysis, software and provide example R code. We conduct simulation studies that mimic the real study to study the operation characteristics of these methods.

stat.ME↗

Use of Non-concurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

This article summarizes the discussions from the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section Open Forum that took place on December 10, 2020 and was organized by the ASA BIOP Statistical Methods in Oncology Scientific Working Group, in coordination with the US FDA Oncology Center of Excellence. Diverse stakeholders including experts from international regulatory agencies, academicians, and representatives of the pharmaceutical industry engaged in a discussion on the use of non-concurrent control in Master Protocols for oncology trials. While the use of non-concurrent control with the concurrent control may increase the power of detecting the therapeutic difference between a treatment and the control, the panelists had diverse opinion on the statistical approaches for modeling non-concurrent and concurrent controls. Some were more concerned about the temporality of the non-concurrent control and bias introduced by different confounders related to time, e.g., changes in standard of care, changes in patient population, changes in recruiting strategies, changes in assessment of endpoints. Nevertheless, in some situations such as when the recruitment is extremely challenging for a rare disease, the panelists concluded that the use of a non-concurrent control can be justified.

stat.AP↗